Trial Profile
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Immune globulin (Primary) ; Mesna (Primary) ; Rituximab (Primary) ; Thiotepa (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 13 Dec 2022 Results(n=4, adolescent and young adult) assessing the effect of Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 17 Dec 2021 Antithymocyte-globulin has been added to the study drug regimen. Inclusion criteria has been updated to change the age limits from 16 - 70 years to 8 years -60 years thus including child population and excluding elderly population.